FHTX — Foghorn Therapeutics Share News
0.000.00%
Last trade - 00:00- $118.77m
- -$48.81m
- $30.91m
Brief: Foghorn Therapeutics Files Prospectus For Issuance & Sale Of Shares Of Up To $100 Million From Time To Time
Foghorn Therapeutics Inc. reports results for the quarter ended December 31 - Earnings Summary
Foghorn Therapeutics Inc. reports results for the quarter ended December 31 - Earnings Summary
Foghorn Therapeutics Inc. expected to post a loss of 33 cents a share - Earnings Preview
Brief: Foghorn Therapeutics Inc. Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Foghorn falls after discontinuing independent development of its cancer treatment
Brief: Foghorn Therapeutics Provides Update On Fhd-286 Clinical Development Program
Foghorn Therapeutics Inc. reports results for the quarter ended in September 30 - Earnings Summary
Brief: Foghorn Therapeutics Q3 EPS USD -0.31
Foghorn Therapeutics Inc. expected to post a loss of 44 cents a share - Earnings Preview
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence
Brief: Foghorn Therapeutics Announces First Patient Dosed With FHD-909 In A Phase 1 Trial For SMARCA4 Mutated Solid Tumors
U.S. RESEARCH ROUNDUP-Commercial Metals, M&T Bank, Simon Property
Brief: Foghorn Therapeutics Q2 EPS USD -0.45
Foghorn Therapeutics Inc. expected to post a loss of 65 cents a share - Earnings Preview
Foghorn Therapeutics Inc. expected to post a loss of 65 cents a share - Earnings Preview
Brief: Foghorn Therapeutics Raises About $110 Mln Through Registered Direct Offering To Advance Pipeline
Brief: Foghorn Announces Pricing Of Registered Direct Offering Of Common Stock And Pre-Funded Warrants
Foghorn Therapeutics Inc. reports results for the quarter ended in March - Earnings Summary